Infection Control Program as an Additional Tool to Control Bacterial Resistance  by Cornejo, P.
e th In
6
E
F
D
c
o
p
n
o
T
b
e
t
e
d
a
c
p
b
e
l
p
g
s
e
t
S
m
r
t
f
e
d
c
c
b
f
d
s
i
d
6
B
t
J
a
a
i
p
c
b
b
o
m
p
i
a
t
i
e
g
(
l
E
t
p
m
i
d
6
I
B
P
s
b
a
a
h
s
c
3
p
D
a
f
t
a
a
s
t
p
m
m
g
t
t
f
t314 14
1.001
xtreme Drug Resistance (XDR) in Nosocomial Pathogens
. Pasteran
Instituto Nacional de Enfermedades Infecciosas INEI ANLIS
r. Carlos G. Malbran, Buenos Aires, Argentina
The implacable increase in the prevalence of antimi-
robial resistance among gran negative bacilli (BGN) is
f great concern. Several highly resistant gram-negative
athogens, namely Acinetobacter, Pseudomonas aerugi-
osa, and Klebsiella pneumoniae sensitive to a small number
f drugs, if not any, are emerging as signiﬁcant pathogens.
he mechanisms of this resistance are often complex
ut include outer-membrane impermeability, up-regulated
fﬂux pumps, target-site mutation and, not surprisingly,
he production of carbapenemases, in addition to several
nzymes. Given the frequency of worldwide reports now
escribing infection with carbapenemase-producing BGN, in
ddition to the intercontinental spread of hyper-epidemic
lones, such as KPC-3-possesing K. pneumoniae ST258, it is
ossible that any institution on the globe could be beset
y multi-resistant BGNs. Proﬁcient methods are needed for
arly detection and conﬁrmation in clinical microbiology
aboratories of multidrug resistant bacteria, specially those
roducing carbapenemases, in any attempt aimed for tar-
eting optimal antimicrobial therapy and controlling their
pread. Therapeutic options for these pathogens are so
xtremely limited. Even now, resistance to new ‘‘salvage’’
herapy, such as tigecycline and colistin is being observed.
everal new terms deﬁnitions have been introduced in the
edical literature to describe this complex scenario: pan-
esistance, extreme-resistance, extensively-resistant.
Although there is no international harmonization of this
erminology, their adequately capture the public awareness
or the desperate need for attention to this problem. As
xpected, mortality rates among patients with infections
ue to these organisms are signiﬁcantly higher than those
aused by sensitive germs. The urgency of the problem is
ompounded by the recognition that fewer new antimicro-
ial agents are introduced each year. Thus, clinicians are
orced to use older drugs for which there is a lack of robust
ata about their effectiveness. The complex nature of this
cenario requires the coordinated efforts of all sectors
nvolved, in any attempt to curb antimicrobial resistance.
oi:10.1016/j.ijid.2010.02.2183
1.002
asic Principles of Implementing an Antibiotic Optimiza-
ion Program
. Cortes
Bogota, Colombia
Antimicrobial stewardship is an important and evolving
spect of patient care and safety programs in hospitals
round the world. A team of involved specialists, including
nfectious diseases physicians, clinical microbiologists, hos-
ital epidemiologists and others, is needed to address this
omplex problem. In United States a clinical pharmacist has
een also claimed to collaborate in this kind of program,
E
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ut in Latin America and other limited-resources areas, lack
f appropiate personnel are part of the limitations to imple-
entation. Two strategies, not to be exclusively applied, are
roposed. Prospective audit with intervention and feedback
s an option, while the use of formulary restriction and pre-
uthorization might be also used. The ﬁrst strategy might be
ime consuming and requires a series of tools to succed. The
mplementation of the program requires administrative and
conomic support and the use of education, development of
uidelines, antimicrobial order forms, de-escalation therapy
which requires an active participation of the microbiology
aboratory), dose optimization, and switch to oral therapy.
ffective use of antimicrobials but also prevention of resis-
ance are the goals to achive in the individualised care of
atients and new targets are being currently deﬁned (phar-
acodynamic objectives). Up to the moment more research
s required to ﬁnd the best ways to achieve these goals.
oi:10.1016/j.ijid.2010.02.2184
1.003
nfection Control Program as an Additional Tool to Control
acterial Resistance
. Cornejo
Instituto Nacional de Cancerologia, Mexico City, Mexico
The combination of effective antimicrobial steward-
hip with a comprehensive infection control program has
een shown to limit the emergence and transmission of
ntimicrobial-resistant bacteria, reducing health care costs.
There are multiple mechanisms postulated by which
ntimicrobial resistance may appear and disseminate within
ospital organisms:
1) Introduction of a resistant organism to a previously
usceptible population; 2) Acquisition of resistance by a sus-
eptible strain: spontaneous mutation or genetic transfer;
) Expression of regulated resistance already present in the
opulation; 4) Selection of resistant subpopulations; and, 5)
issemination or spread of resistant organisms
There have been proposed ﬁve strategic goals to optimize
ntimicrobial use: 1) Optimize antimicrobial prophylaxis
or surgery 2) Optimize choice and duration of empirical
herapy; 3) Improve prescribing by education; 4) Monitor
nd feedback information on antimicrobial resistance rates,
nd, 5) Produce protocols for antibiotic usage. Also the
trategies must include optimal selection, dose, and dura-
ion of treatment, as well as control of antibiotic use, for
revention or slowing the emergence of resistant among
icroorganisms.
An effective Antimicrobial Control Program Infection
ust prevent or reduce antimicrobial resistance. Speciﬁc
oals related to this program are:
1) A determination of who will be responsible for main-
aining control. 2) A determination of which antimicrobial(s)
o control. 3) Precise deﬁnitions of antimicrobial resistance
or antimicrobials and organisms. 4) A system for monitoring
he frequency of resistance (clinical and environmental). 4)
ducation. It is an essential element to inﬂuence prescrib-
ng behavior. 5) A method to determine antimicrobial use
er geographic area per unit time. 6) Ability to distinguish
ommunity from nosocomial isolates. 7) A method to assure
trac
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that clinical care will not be harmed by control measures
such as: de-escalation of therapy, dose optimization, and
parenteral to oral conversion of antimicrobials with excel-
lent bioavailability can decrease the length of hospital stay
and health care costs.
doi:10.1016/j.ijid.2010.02.2185
61.004
New Antibiotics: Which Role in a Antimicrobial Steward-
ship Program?
D. Curcio
Hospital de Infecciosas F.J. Muniz, Buenos Aires, Argentina
Infections caused by multidrug-resistant bacteria con-
tinue to challenge physicians in the daily practice. We
face growing resistance among Gram-positive and Gram-
negative pathogens that cause infection in the hospital
and in the community. Rice recently reported these as
the ‘‘ESKAPE’’ pathogens (Enterococcus faecium, Staphy-
lococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumanii, Pseudomonas aeruginosa, and Enterobacter
species) to emphasize that they currently cause the majority
of world-wide hospital infections and effectively ‘‘escape’’
the effects of antibacterial drugs.
In this context, controlling antibiotic use and bacterial
resistance trough an antibiotic stewardship program (ASP)
is of major importance to all professionals involved in infec-
tious diseases.
A critical need to develop new antimicrobial compounds
and to use the recently approved agents appropriately are
components of all ASP. Unfortunately, most of the agents
which are in the late stage of develop have activity only
against Gram-positives and none is active for treatment of
infections caused by the Gram-negative ESKAPE pathogens.
We have analized the body of the literature with the aim
to deﬁne, within a ASP, the opportunity of use and the poten-
tial advantages of new antibiotics in order to reduce the
emergence and selection of resistant pathogens.
Related with the role of the new antibiotics in a Asp, it is
possible to consider the following points: i-the use of tige-
cycline instead of carbapenems in clinical settings with high
rates of carbapenems-resistant pathogens (ie. in nosocomial
peritonitis), ii-the use of doripenem in extended-infusion
(ie. in severe infections due to Pseudomonas aeruginosa);
iii-the use of daptomycin at high doses (ie. in infections
due to methicillin-resistant Staphylococcus aureus) and iv-
the use of ceftobiprole as empiric monotherapy (ie. in some
suspected mixed infections).
The use of the new antibiotics in the daily practice
based on the individual patient characteristics, causative
organism, site of infection, and pharmacokinetic and phar-
macodynamic characteristics of the drug is an important
part of an ASP.
doi:10.1016/j.ijid.2010.02.2186
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2.001
tate of the Art on ARV Therapy: How Many Standards of
are?
. Cahn
Foundation Huesped, Buenos Aires, Argentina
Albeit nobody would support the idea of ‘‘ﬁrst and second
lass medicine’’, in real life we confront AIDS with at leat
wo standards of care. When to start ARV therapy remains a
atter of debate. No disagreement exists for symptomatic
atients, as well as for asymptomatic individuals with CD4
ounts of 350/ mm3 or below. In resource-poor settings,
HO recommended until late 2009 that adolescents and
dults should start HAART when they have advanced HIV
isease, mildly symptomatic and asymptomatic disease,
HO Stage II or I HIV disease with CD4 counts <200/mm3
These recommendations were updated in November 2009
nd look now closer to those released by other interna-
ional bodies. Some Western countries guidelines panels,
ike the DHHS recommends now treatment initiation in
symptomatic patients when the CD4 count falls below
50/mm3, and have shown a divided opinion regarding the
f treatment should be considered in patients with CD4
ell counts <500/mm3, particularly if the patient has high
iral load, age above 50 and/or comorbidities like HBV or
CV coinfections, among others. Increasing amount of data
uggest that by starting earlier, the so called ‘‘non-AIDS’’
iseases driving to mortality in the HAART era might be dra-
atically reduced. On top of the beneﬁts at the individual
evel, ART has been shown as a prevention tool by reduc-
ng the median viral load at the community level.Currently
vailable co formulations are the best options for ARV back-
one in naive patients. Issues such as childbearing potential
nd baseline resistance need to be taken into consideration
hen selecting a regimen. Controversies remain on whether
o use a PI or an NNRTI as the third drug in initial therapy,
articularly important in the presence of advanced disease.
he bottom line is that one size does not ﬁt for all in this
hallenging ﬁeld.
oi:10.1016/j.ijid.2010.02.2187
2.002
rug Resistance and Other Laboratory Monitoring Assays
n HIV infection
. Hirsch
Harvard Medical School, Boston, MA, USA
Although CD4 cell counts and plasma viral load assays
re the principal laboratory tests used to monitor the
rogress of HIV-1 infections, several other assays are assum-
ng increasing importance to adequately assess the beneﬁts
f antiretroviral therapy (ART) in infected individuals. The
ccessibility of such assays will vary greatly, depending on
he resources available to treat HIV infections.
Where testing capability exists, HIV drug resistance test-
ng is useful when patients enter care prior to initiating
herapy and again when considering change of regimens
